BRIEF—WuXi STA to build new R&D center in Shanghai

Chinese research and development platform company WuXi AppTec subsidiary STA Pharmaceuticals has signed an investment agreement with the government of Shanghai, Jinshan District to build a new R&D center.

The new facility will further strengthen WuXi STA’s global leading pharmaceutical development and manufacturing platform, enabling drug developers to accelerate their projects from preclinical to commercial stage.

WuXi STA has already established an industry leading process development platform with over 1,000 scientists and five sites located in China and the USA. The company’s Jinshan site currently focuses on manufacturing innovative Active Pharmaceutical Ingredients (APIs) and advanced intermediates from kilo to metric ton scale. The site has been approved by multiple international regulatory agencies, including the US Food and Drug Administration.

The new R&D center will be located next to the existing Jinshan drug substance manufacturing site, adding more than 30,000 square meters of laboratory space and 500 scientists.

No financial terms of the project have been disclosed.

On completion, the expanded Jinshan campus will be able to offer an integrated one-site solution for partners to push forward innovative APIs and advanced intermediates – from preclinical and clinical development through to global commercial launch. The new campus will also provide access to industry-leading technology platforms such as flow chemistry, biocatalysis, and high potency from laboratory to commercial scale.